PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Recruiting

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(30 sites)

United States

University of California, San Diego Health, La Jolla, California

Stanford University School of Medicine, Palo Alto, California

UCSF, San Francisco, California

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California

Yale University, New Haven, Connecticut

The Cardiac and Vascular Institute, Gainesville, Florida

University of Florida, Gainesville, Florida

Tallahassee Research Institute, Tallahassee, Florida

Rush University Medical Center, Chicago, Illinois

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

UMass Chan Medical School, Worcester, Massachusetts

Washington University / Barnes Jewish, St Louis, Missouri

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Vascular Institute of Atlantic Medical Imaging, Pomona, New Jersey

Holy Name Medical Center, Teaneck, New Jersey

Presbyterian Healthcare, Albuquerque, New Mexico

Northwell Health Long Island Jewish Medical Center, Lake Success, New York

NYU Langone Health, New York, New York

Mount Sinai, New York, New York

Cornell University, New York, New York

Atrium Health, Charlotte, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Penn State Health, Hershey, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

UT Southwestern Medical Center, Dallas, Texas

Sentara Norfolk General Hospital, Norfolk, Virginia

Ascension Columbia St. Mary's Hospital, Milwaukee, Wisconsin

The Medical College of Wisconsin, Milwaukee, Wisconsin